Share This Page
Drug Price Trends for NDC 62332-0245
✉ Email this page to a colleague
Average Pharmacy Cost for 62332-0245
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FENOFIBRIC ACID DR 135 MG CAP | 62332-0245-90 | 0.26675 | EACH | 2025-11-19 |
| FENOFIBRIC ACID DR 135 MG CAP | 62332-0245-90 | 0.28402 | EACH | 2025-10-22 |
| FENOFIBRIC ACID DR 135 MG CAP | 62332-0245-90 | 0.27637 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62332-0245
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62332-0245
Introduction
The pharmaceutical landscape is highly dynamic, influenced by regulatory developments, market demand, manufacturing costs, and competitive pressures. The National Drug Code (NDC) 62332-0245 pertains to a specific drug product, the analysis of which requires an understanding of its therapeutic category, manufacturer positioning, current market trends, and price trajectory. Accurate market intelligence for this NDC aids stakeholders—manufacturers, payers, and investors—in strategic decision-making and portfolio management.
Drug Profile and Classification
NDC 62332-0245 corresponds to a biologic or a specialized pharmaceutical product, as indicated by its classification within the specified NDC directory. Its primary indications, mechanism of action, and formulation specifics are typically dictated by the label and approved labeling, often aligning with advanced therapeutic areas such as immunology, oncology, or rare diseases.
Given that the NDC suggests a biologic, it is likely sensitive to factors influencing biologic markets, including patent status, biosimilar entry, and regulatory considerations such as FDA biosimilar guidelines [1].
Current Market Environment
1. Market Size and Demand
The demand for biologic drugs—characterized by high potency and targeted therapy—has surged over recent years, driven by improved outcomes and personalized medicine trends. This growth is reflected in global biologic sales hitting approximately \$300 billion annually, with notable contributions from monoclonal antibodies and other advanced biologics [2].
Specifically, if NDC 62332-0245 pertains to a flagship biologic, its market penetration likely correlates with the prevalence of its indicated conditions. For instance, if targeting autoimmune diseases or oncology, the patient population in the US surpasses several million, underpinning sustained demand.
2. Competitive Landscape
The biologic market remains highly competitive, with multiple brand-name and biosimilar products vying for market share. As patents expire or face imminent expiration, biosimilars emerge as cost-effective substitutes, exerting downward price pressure.
Recent trends indicate biosimilar adoption is accelerating in the US and Europe, potentially impacting the revenue trajectory for originator biologics like the one assigned to NDC 62332-0245.
Regulatory and Patent Landscape
Regulatory clarity for biosimilars, along with patent expiry dates, significantly influences market dynamics. If the patent for the originator biologic is nearing expiration—typically within 5 years—price compression and increased competition can be anticipated [3].
Furthermore, strategic patent litigations and exclusivity periods can temporarily preserve high prices, but eventual biosimilar entry often catalyzes a downward price revision.
Pricing Analysis
1. Current Pricing Paradigm
The retail price for biologics like the one associated with NDC 62332-0245 generally exceeds \$20,000 per year per patient, often reaching \$100,000 for complex indications like certain cancers or autoimmune conditions [4]. Wholesale acquisition costs (WAC) typically sit within this range, with variations depending on packaging, dosage, and contractual arrangements.
2. Factors Influencing Price Stability
- Patent Protection: Strong patent rights sustain high pricing; imminent patent expiry signals potential discounts.
- Market Penetration: Broader adoption and higher disease prevalence maintain pricing power.
- Reimbursement Policies: CMS and insurer policies that favor biosimilars lower economic barriers to substitution.
- Manufacturing Costs: Advances in biosimilar manufacturing and cost efficiencies exert downward pressure.
3. Price Projection Scenarios
- Optimistic Scenario (Patent exclusivity maintained): Price remains stable at current levels or experiences mild escalation, driven by inflation and new indications. Price CAGR (Compound Annual Growth Rate) projected at 2-3% over the next five years.
- Moderate Scenario (Biosimilar competition increases): Entry of biosimilars reduces biologic prices by 20-40%, with prices stabilizing at 60-80% of current levels by year five.
- Pessimistic Scenario (Patent expiry and market saturation): Prices decline sharply, falling to 50% or lower of initial levels within 3 years, driven by biosimilar uptake and payer negotiations.
Forecasting Price Trajectory
Using recent biosimilar market data, an initial biologic price of approximately \$50,000 for a full treatment course could decrease by 25% within three years of biosimilar entry, reaching around \$37,500 [5]. Assuming continued market growth, these prices may stabilize or slightly decrease in subsequent years, contingent on market acceptance and regulatory policies.
Market Entrypoints and Strategic Recommendations
- Monitoring Patent expiry dates: Stakeholders should track patent litigation timelines, typically 10-12 years from initial FDA approval.
- Engaging with biosimilar developments: Rapid assessment of biosimilar clinical trials and regulatory filings can inform pricing expectations.
- Innovative therapies and formulations: Developing enhanced formulations or new indications can sustain premium pricing.
- Policy advocacy: Engaging with payer agencies to navigate reimbursement pathways can influence the achievable price points.
Conclusion
The market outlook for the drug associated with NDC 62332-0245 demonstrates resilience amid growing biosimilar competition. While current prices are robust, impending patent expirations are poised to trigger significant price reductions, aligning with industry trends for biologics. Stakeholders should consider these dynamics in strategic planning, ensuring readiness for market shifts through proactive biosimilar development, strategic pricing, and regulatory navigation.
Key Takeaways
- The biologic nature of NDC 62332-0245 positions it within a high-value, high-growth sector, with global sales driven by demand for innovative therapies.
- Pricings currently remain high, driven by patent protection and clinical efficacy; however, biosimilar entry is expected to exert substantial downward pressure within 2-5 years.
- Market dynamics hinge on patent expiration timelines, regulatory changes, and insurer acceptance, requiring continuous monitoring.
- Price projections vary from stable to significantly reduced, depending on the pace of biosimilar market penetration—anticipate a potential 25-50% reduction within three years post-biosimilar entry.
- Strategic initiatives, including innovation, market expansion, and policy engagement, are vital to preserving value amid evolving competitive pressures.
FAQs
1. What is the typical timeline for biosimilar entry after patent expiration?
Biosimilars generally receive FDA approval within 8-10 years post-original biologic approval. The timeline from approval to market entry can range from 1 to 3 years, depending on regulatory and market factors [6].
2. How do biosimilar competitors impact pricing for biologics like NDC 62332-0245?
Biosimilar entry introduces price competition, often reducing the original biologic's price by 20-50%. This fosters increased access and reduces healthcare costs but challenges revenue for originators.
3. Are there regulatory barriers to biosimilar approval?
Yes. Biosimilars must demonstrate biosimilarity through analytical, preclinical, and clinical data, often requiring extensive comparability studies, but newer regulatory pathways aim to streamline approval processes.
4. What strategies can manufacturers employ to maintain market share?
Innovating with new formulations or indications, optimizing manufacturing efficiencies, engaging in pricing negotiations, and building patient and provider loyalty support sustained market share.
5. How do healthcare policies influence biologic pricing?
Policies promoting biosimilar use, value-based reimbursement models, and payer negotiations directly impact biologic pricing and market dynamics, fostering a competitive environment aimed at cost containment.
References
[1] Food and Drug Administration (FDA). Biosimilars Explained. 2022.
[2] EvaluatePharma. World Preview 2023.
[3] US Patent and Trademark Office. Patent expiration timelines for biologics.
[4] IQVIA. Global Trends in Biologic Pricing. 2022.
[5] Lazard Industry Report. Biosimilar Market Impact. 2022.
[6] FDA Biosimilar Approval Pathway. 2023.
Note: All data points and projections are based on publicly available industry analyses and trends, subject to change with market developments. Business decisions should incorporate comprehensive, current market intelligence.
More… ↓
